A pilot study of topotecan in the treatment of serous carcinoma of the uterus

International Journal of Gynecological Cancer

Volumn 13, Issue 2, 2003, Pages 216-222

  Chambers, Joseph T ^a,b   Rutherford, T J ^a   Schwartz, P E ^a   Carcangiu, M L ^a   Chambers, S K ^a   Baker, L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

Hycamtin; Myelosuppression; Topoisomerase I inhibitor; Topotecan; Uterine serous carcinoma

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; DEXAMETHASONE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ERYTHROPOIETIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; ONDANSETRON; PROCHLORPERAZINE MALEATE; TOPOTECAN; ANTINEOPLASTIC AGENT; PLATINUM;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER REGRESSION; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; FEMALE; HUMAN; HUMAN TISSUE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PILOT STUDY; POSTOPERATIVE CARE; PRIORITY JOURNAL; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT FAILURE; UTERUS CARCINOMA; VOMITING; CLINICAL TRIAL; CYSTADENOCARCINOMA; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG RESISTANCE; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME; UNITED STATES; UTERUS CANCER;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CYSTADENOCARCINOMA, PAPILLARY; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEW YORK CITY; PILOT PROJECTS; PLATINUM; SURVIVAL ANALYSIS; TOPOTECAN; TREATMENT OUTCOME; UTERINE NEOPLASMS;

EID: 0038306997     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.2003.13022.x     Document Type: Article

References (27)

1. Kato DT, Ferry JA, Goodman A et al. Uterine papillary serous carcinoma (UPSC): A clinicopathologic study of 30 cases. Gynecol Oncol 1995;59:384-9.
2. Sutton GP, Brill L, Michael H, Stehman FB, Ehrlich CE. Malignant papillary lesions of the endometrium. Gynecol Oncol 1987;27:294-304.
3. Carcangiu ML, Chambers JT. Early pathologic stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium: comparison of clinicopathologic features and survival. Int J Gynecol Pathol 1995;14:30-8.
4. Rosenberg P, Blom R, Hogberg T, Simonsen E. Death rate and recurrence pattern among 841 clinical stage I endometrial cancer patients with special reference to uterine papillary serous carcinoma. Gynecol Oncol 1993;51:311-5.
5. Goff BA, Kato D, Schmidt RA et al. Uterine papillary serous carcinoma: Patterns of metastatic spread. Gynecol Oncol 1994;54:264-8.
6. Frank AH, Tseng PC, Haffty BG et al. Adjuvant whole-abdominal radiation therapy in uterine papillary serous carcinoma. Cancer 1991;68:1516-9.
7. Mallipeddi P, Kapp DS, Teng NN. Long-term survival with adjuvant whole abdominopelvic irradiation for uterine papillary serous carcinoma. Cancer 1993;71:3076-81.
8. Umpierre SA, Burke TW, Tornos C, Ordonez N, Levenback C, Morris M. Immunocytochemical analysis of uterine papillary serous carcinomas for estrogen and progesterone receptors. Int J Gynecol Pathol 1994;13:127-30.
9. Carcangiu ML, Chambers JT, Voynick IM, Pirro M, Schwartz PE. Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part I. clinical and histologic correlations. Am J Clin Pathol 1990;94:247-54.
10. Chambers JT, Chambers SK, Kohorn EI, Carcangiu ML, Schwartz PE. Uterine papillary serous carcinoma treated with intraperitoneal cisplatin and intravenous doxorubicin and cyclophosphamide. Gynecol Oncol 1996;60:438-42.
11. Levenback C, Burke TW, Silva E et al. Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC). Gynecol Oncol 1992;46:317-21.
12. Price FV, Chambers SK, Carcangiu ML, Kohorn EI, Schwartz PE, Chambers JT. Intravenous cisplatin, doxorubicin, and cyclophosphamide in the treatment of uterine papillary serous carcinoma (UPSC). Gynecol Oncol 1993;51:383-9.
13. McGuire WP, Blessing JA, Bookman MA, Lentz SS, Dunton CJ. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2000;18:1062-7.
14. Swisher EM, Mutch DG, Rader JS, Elbendary A, Herzog TJ. Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol 1997;66:480-6.
15. Bookman MA, Malmström H, Bolis G et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998;16:3345-52.
16. ten Bokkel Huinink W, Gore M, Bolis G et al. A phase II trial of topotecan for the treatment of relapsed advanced ovarian carcinoma. Proc Am Soc Clin Oncol 1996;15:284 (Abstract).
17. Price FV, Chambers SK, Carcangiu ML, Kohorn EI, Schwartz PE, Chambers JT. CA125 may not reflect disease status in patients with uterine serous carcinoma. Cancer 1998;82:1720-5.
18. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982;6:93-108.
19. Chambers JT, Merino M, Kohorn EI, Peschel RE, Schwartz PE. Uterine papillary serous carcinoma. Obstet Gynecol 1987;69:109-13.
20. Christman JE, Kapp DS, Hendrickson MR, Howes AE, Ballon SC. Therapeutic approaches to uterine papillary serous carcinoma: a preliminary report. Gynecol Oncol 1987;26:228-35.
21. Carcangiu ML, Tan LK, Chambers JT. Stage IA uterine serous carcinoma: a study of 13 cases. Am J Surg Pathol 1997;21:1507-14.
22. Stringer CA, Gershenson DM, Burke TW, Edwards CL, Gordon AN, Wharton JT. Adjuvant chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (PAC) for early-stage high-risk endometrial cancer: a preliminary analysis. Gynecol Oncol 1990;38:305-8.
23. Zanotti KM, Belinson JL, Kennedy AW, Webster KD, Markman M. The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma. Gynecol Oncol 1999;74:272-7.
24. Ramondetta L, Burke TW, Levenback C, Bevers M, Bodurka-Bevers D, Gershenson DM. Treatment of uterine papillary serous carcinoma with paclitaxel. Gynecol Oncol 2001;82:156-61.
25. Miller DS, Blessing JA, Lentz SS, Waggoner SE. A phase II trial of topotecan in patients with advanced, persistent or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Proc Am Soc Clin Oncol 2001;20:179b. (Abstract).
26. Miyamoto S, Huang TT, Wuerzberger-Davis S et al. Cellular and molecular responses to topoisomerase I poisons. Exploiting synergy for improved radiotherapy. Ann N Y Acad Sci 2000;922:274-92.
27. Chastagner P, Merlin JL, Marchal C et al. In vivo potentiation of radiation response by topotecan in human rhabdomyosarcoma xenografted into nude mice. Clin Cancer Res 2000;6:3327-33.